Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.
about
Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis.Genetic and epigenetic studies of adiposity and cardiometabolic disease.Bone mineral density and risk of type 2 diabetes and coronary heart disease: A Mendelian randomization study.Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke.Recent Developments in Mendelian Randomization Studies.Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver.Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis.Genetic architecture: the shape of the genetic contribution to human traits and disease.HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics.Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease.Assessing causal relationships using genetic proxies for exposures: an introduction to Mendelian randomization.Genetic Support for a Causal Role of Insulin Resistance on Circulating Branched-Chain Amino Acids and Inflammation.Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities.Heterogeneity in effects of genetically determined adiposity on insulin resistance and type 2 diabetes: The atherosclerosis risk in communities study.Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer's disease: A prospective study in eight cohorts.Genetic markers for urine haptoglobin is associated with decline in renal function in type 2 diabetes in East Asians.The MR-Base platform supports systematic causal inference across the human phenome.Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians.Influence of puberty timing on adiposity and cardiometabolic traits: A Mendelian randomisation studyEvaluating the potential role of pleiotropy in Mendelian randomization studiesProblems in interpreting and using GWAS of conditional phenotypes illustrated by 'alcohol GWAS'Mendelian Randomization Studies of Coffee and Caffeine ConsumptionClarifying questions about "risk factors": predictors versus explanationCOSMIC project: consensus on the objectives of the metabolic syndrome in clinic
P2860
Q38614073-7FB19290-621E-464A-851A-1E3EB1A6FFE6Q41706075-276F34E2-5F00-450E-BFBF-7CB466A151E7Q42361203-67063519-D962-4F42-917C-084FC6FED5B5Q45069779-B1E45CAE-5653-4B9A-8695-6AB526163BCFQ47158618-490080FC-789C-47FA-8818-637266779545Q47245103-7E34B0B4-566C-4541-98DE-FE8751C3D6E9Q47394015-45E67E00-56FD-4FDD-8097-DFBD1129E5C7Q47579970-75D1F510-C63B-4A36-B870-5F46FA9274DBQ47657807-461DFAF5-B677-4AB2-A14C-F0D03ED5FAC7Q47666098-54573239-2299-4A66-B7F2-308A4FA20FA9Q47690063-4FAB631F-77E8-4417-8B9A-1775947B699BQ47766312-9ECBEAE3-0F5A-4A04-96EE-326F4E214C71Q47776394-7E618073-21A4-4692-9D88-3DD5346272C6Q50207754-3704EB50-2841-4E45-9422-6CEC71ABE2EBQ51764769-C001DEC8-48A7-4B4E-A9B3-F8E2C2556DD5Q52639416-9A1B6D32-D600-4133-8B3E-ED9F3C13D769Q55427190-0D525F8A-8CA0-421A-BA3D-0E4D361306A2Q55645726-14A98DA4-9B11-4983-BD43-DA380D8CCA5DQ57101467-70233545-2A22-4CE3-A755-F2785FBB06EFQ57101556-98B4884A-D221-4F4B-B804-50093A23E41AQ57101944-B90992EE-30CF-4CE4-AC53-9586B70F4215Q58708378-77F1FB2E-574C-47CA-B2CD-92EE20FDED3EQ58795840-DF4A1C45-59DC-46BE-BC46-1C748C246214Q59125991-B314ECEA-818B-4054-8B3F-9783DA58424C
P2860
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.
@ast
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.
@en
type
label
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.
@ast
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.
@en
prefLabel
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.
@ast
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.
@en
P2860
P356
P1476
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.
@en
P2093
Michael V Holmes
P2860
P304
P356
10.1038/NRCARDIO.2017.78
P407
P577
2017-06-01T00:00:00Z